Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

890
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
890
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

10.4K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
10.4K
Spare Receptors01:30

Spare Receptors

4.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.8K
Local Anesthetics: Pharmacokinetics01:13

Local Anesthetics: Pharmacokinetics

1.4K
The potency and duration of action of local anesthetics (LAs) are determined by their pharmacokinetics. Pharmacokinetics describes how LAs are absorbed, distributed, metabolized, and eliminated from the body. When administered to the vascular tissues, LAs are quickly absorbed and enter the systemic circulation, reducing their localized effects. Adding vasoconstrictors such as epinephrine to LAs reduces their absorption into the systemic circulation, making them clinically effective. The...
1.4K
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

4.3K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
4.3K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

235
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electrosynthesis of Silver Particles-Polypyrrole on Screen-Printed Carbon Electrodes, with a View to Their Modification with Ki-67 Antibodies.

Polymers·2026
Same author

Dietary Terpenoid Lactones are Promiscuous Agonists of Bitter Taste Receptors (TAS2Rs).

Journal of natural products·2026
Same author

Myrrhain A: Structural Reassignment Highlights the Relevance of Plasticizer Contamination in Chemical and Bioactivity Studies.

Organic letters·2025
Same author

Are Furanocoumarins Present in the Cichorieae Tribe of Asteraceae? A Comparative Study of <i>Cicerbita alpina</i> (Asteraceae) and <i>Peucedanum ostruthium</i> (Apiaceae).

Plants (Basel, Switzerland)·2025
Same author

Cannabidiol improves metabolic profiles and alleviates liver inflammation and fibrosis in conditions of androgenic obesity and polycystic ovary syndrome.

Diabetes, obesity & metabolism·2025
Same author

Analytically Unsupervised Metabolomic Profile of the Premium Malgasy Pepper Voatsipérifery (<i>Piper borbonense</i>): Identification of Marker Components.

Journal of agricultural and food chemistry·2025

Related Experiment Video

Updated: Mar 13, 2026

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

7.1K

Phytocannabinoids: a unified critical inventory.

Lumír Ondřej Hanuš1, Stefan Martin Meyer2, Eduardo Muñoz3

  • 1Institute for Drug Research, School of Pharmacy, Faculty of Medicine, Hebrew University, Ein Kerem Campus, Jerusalem 91120, Israel. lumirh@ekmd.huji.ac.il.

Natural Product Reports
|October 11, 2016
PubMed
Summary
This summary is machine-generated.

Cannabis sativa L. produces diverse phytocannabinoids. Their structural diversity may arise from non-enzymatic degradation of major compounds, offering therapeutic potential beyond CB1 receptor targets.

More Related Videos

Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

627

Related Experiment Videos

Last Updated: Mar 13, 2026

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass
05:46

Ultrasonic-Assisted Extraction of Cannabidiolic Acid from Cannabis Biomass

Published on: May 27, 2022

7.1K
Administration of &#916;9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

1.2K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

627

Area of Science:

  • Phytochemistry
  • Natural Product Chemistry
  • Pharmacology

Background:

  • Cannabis sativa L. produces a wide array of phytocannabinoids.
  • Phytocannabinoid structural definitions are complex due to variations in side-chains and isoprenyl residues.
  • Existing definitions are challenged by the modular biosynthetic pathways.

Purpose of the Study:

  • Propose a biogenetic definition for phytocannabinoids.
  • Explore the structural diversity and origins of cannabis phytocannabinoids.
  • Investigate the therapeutic potential of phytocannabinoids beyond CB1 receptor agonism.

Main Methods:

  • Review of existing literature on phytocannabinoid biosynthesis and structure.
  • Analysis of proposed biogenetic pathways for phytocannabinoid classification.
  • Discussion of non-enzymatic degradation pathways for major phytocannabinoids.
  • Inventory of biological targets for phytocannabinoids.

Main Results:

  • A biogenetic classification is proposed, dividing phytocannabinoids into alkyl and β-aralklyl types.
  • Structural diversity may result from heat, light, and oxygen-induced degradation of key compounds like CBG, CBD, THC, and CBC.
  • Phytocannabinoids interact with diverse targets including cannabinoid receptors, thermos-TRPs, and PPARs.

Conclusions:

  • The structural diversity of cannabis phytocannabinoids is significant and potentially influenced by degradation.
  • Phytocannabinoids offer a broad range of drug-like properties targeting multiple biological pathways.
  • These compounds present opportunities for developing therapeutics beyond the scope of CB1 receptor modulation.